# To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects

> **NCT01409616** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 100 (actual)

## Conditions studied

- Pharmacodynamic Interaction
- Healthy Subjects

## Interventions

- **DRUG:** darexaban
- **DRUG:** darexaban (double dose)
- **DRUG:** Acetyl Salicylic Acid
- **DRUG:** clopidogrel

## Key facts

- **NCT ID:** NCT01409616
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01409616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01409616, "To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01409616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*